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Nucleoside Based Self-Assembling Drugs for Localized Drug 
Delivery  
 K. J. Skilling,[a] M. J. Stocks,[a] B. Kellam,[a] M. Ashford,[b] T. D. Bradshaw,[a] L. Burroughs [a] and M. Marlow* [a]
Abstract: We have synthesized a range of gelators based on 
nucleoside analogues gemcitabine and lamivudine, characterizing 
representative gels from the series using rheology and TEM. 
Growth inhibition studies of gemcitabine derivatives confirmed 
the feasibility of these compounds as novel treatments, indicating 
the potential of nucleoside based gelators for localized drug 
delivery. 
Defined as structures possessing “a continuous microscopic 
structure with macroscopic dimensions that are permanent and 
solid-like in rheological behaviour despite being derived from 
systems that were mostly liquid”,1 gels are a diverse class of multi-
component molecular systems. In the simplest terms, they 
contain both liquid and a solid 3D matrix.  
Low molecular weight gels (LMWGs) are formed by the self-
assembly of low molecular mass molecules (≤ 3000 gmol-1), and 
contain small amounts (typically < 2 wt%) of gelator in 
combination with an organic and/or aqueous liquid.2 The gelator 
self-assembles in the liquid to form a continuous phase governed 
by non-covalent interactions such as π-stacking, hydrogen 
bonding and dispersion forces.3 These reversible interactions 
make LMWGs attractive agents for a range of applications 
including drug delivery, tissue engineering, catalysis, green 
chemistry, chemical sensors and electronics, as they can be 
designed to gelate under very specific and/or mild conditions.4, 5, 
6 LMWGs therefore offer immense potential for novel, highly-
specific drug delivery systems via: 1) drug encapsulation with 
diffusion and/or degradation release,7 2) covalent binding of drug 
molecule(s) released by bond cleavage upon interaction with 
target stimulus,8 or 3) prodrug gelator compounds that form active 
systems when self-assembled (therapeutic molecular gels).9, 10, 11, 
12, 13 
With LMWG drug delivery systems, the ability of gels to 
remain localized in vivo allows for greater site-specific delivery 
and can vastly increase drug efficacy while minimising adverse 
systemic toxicity. We proposed to synthesise a library of potential 
gelator derivatives of gemcitabine 1 and lamivudine 2 as shown 
in Figure 1. We hypothesized that a LMWG derived from 
chemotherapeutic gemcitabine 1 would allow for the development 
of an intra-tumoral therapy, potentially enhancing in vivo drug 
activity. Simultaneously, this approach could hinder the first-pass 
metabolism of gemcitabine by cytidine deaminase (CDA) and 
deoxycytidine deaminase (dCDA). We also believed a LMWG 
derived from a HIV antiretroviral lamivudine 2 would allow for the 
development of a topical pre-exposure treatment applied 
vaginally to protect the user from HIV infections. Vaginal drug 
delivery has been highlighted as an important tool in the fight 
against HIV and AIDS,14 with studies such as the CAPRISA 004 
Tenofovir gel trial indicating that prevention of male-to-female 
sexual transmission of HIV-1 is achievable using this approach.15 
Figure 1. Proposed derivatives of gemcitabine 1 and lamivudine 2. 
Most importantly, the Tenofovir gel is a simple cellulose-based 
aqueous gel and retention in the vagina is often poor. Hence, 
there is clearly a need for new and innovative approaches to 
vaginal gel formulation that addresses this deficiency. 
In order for a system to successfully form gels a balance of non-
covalent interactions and solubility is required, illustrated by the 
fact that gelators are usually only able to form gels in a narrow 
range of solvents.16 The gemcitabine 1 core contains multiple 
hydrogen bond donor and acceptor groups and a pyrimidine base 
allowing for π-stacking that we believed would facilitate creation 
of a self-assembled network; introduction of alkyl groups to the 
system would decrease aqueous solubility and create the 
solvophobic forces necessary for gelation under aqueous 
conditions.3, 4 Ester prodrugs are commonly synthesized in order 
to enhance lipophilicity, increasing passive membrane 
permeability of water soluble drugs.17 The ester moiety is also 
readily hydrolysed under physiological conditions, and multiple 
examples of efficacious gemcitabine-ester prodrugs have been 
reported.18, 19, 20 We decided to synthesise ester derivatives of the 
5’-hydroxyl group (Table 1, entries 1-5) as previous studies have 
shown the importance of the 2’-hydroxyl group for gelation of the 
inert analogue 2’-deoxycytidine.21 Acylation of the 5’-hydroxyl 
group could also be achieved in one pot from gemcitabine 1 using 
enzymatic esterification.22 Chain lengths ranging from 
tetradecanoyl (2a) to hexanoyl (2e) were chosen to provide 
varying degrees of hydrophobicity.  
By blocking the site of potential deamination, modification of 
the 4-amino position affords the opportunity to increase both 
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Table 1. Synthesized Derivatives of Lamivudine 2 and Gemcitabine 1. 
 
Entry R %Yield[a] %Purity[b] cLogP[c] LogSw[c] Entry R %Yield[a] %Purity[b] cLogP[c] LogSw[c] 
1 3a (CH2)12CH3 89 99 5.88 -4.78 11 5a (CH2)5CH3 28 97 2.36 -2.83 
2 3b (CH2)10CH3 77 98 4.82 -4.55 12 5b (CH2)3CH3 29 95 1.30 -2.00 
3 3c (CH2)8CH3 66 98 3.77 -4.03 13 5c CH2CH(CH3)CH3 26 95 1.17 -1.83 
4 3d (CH2)6CH3 95 99 2.71 -3.20 14 6a (CH2)13CH3 55 96 5.38 -5.10 
5 3e (CH2)4CH3 70 >99 1.65 -2.37 15 6b (CH2)11CH3 55 98 4.32 -4.28 
6 4a (CH2)12CH3 55 98 5.80 -5.77 16 6c (CH2)7CH3 53 96 3.26 -3.45 
7 4b (CH2)10CH3 23 99 4.74 -5.19 17 6d (CH2)5CH3 36 97 2.21 -2.62 
8 4c (CH2)8CH3 41 99 3.68 -4.59 18 6e (CH2)3CH3 26 96 1.15 -1.79 
9 4d (CH2)6CH3 42 99 2.62 -3.97 19 7a (CH2)6CH3 56 >99 1.87 -3.00 
10 4e (CH2)4CH3 43 99 1.56 -3.33 20 7b (CH2)8CH3 31 99 2.93 -3.83 
21 7c (CH2)10CH3 44 >99 3.98 -4.66 
[a] Yield of purified compound isolated after flash column chromatography. [b] Determined by RP-HPLC on a Phenomenex Luna C8 column. [c] Calculated using 
ACD/Labs software. 
 
chemical and enzymatic stability of gemcitabine 1. Amide, 
carbamate and urea derivatives at the 4-amino position were 
therefore also chosen (Table 1, entries 6-10, 11-13 and 14-18 
respectively) as their greater enzymatic stability generally allows 
for increased half-lives over those of their respective esters. We 
postulated that the increased stability to hydrolysis of these 
derivatives may potentially allow for lower doses and a prolonged 
therapeutic effect. Indeed, examples of gemcitabine N-amides 
have been shown to exhibit cytotoxicity in vivo and increased 
metabolic stability,23, 24 with 4-N-alkanoyl gemcitabine derivatives, 
similar to those synthesised here showing similar in vitro cell 
growth inhibition with IC50 values in the low nanomolar range and 
comparable to the parent compound.25 Also 4-N-acylated 
squalene derivatives of gemcitabine self-assembled in water into 
nano assemblies that showed superior anticancer properties in a 
preclinical leukeamia model.26 In a similar manner vitamin E 
conjugated to gemcitabine via the N4-amino group also formed 
nano assemblies that showed increased growth inhibition against 
a pancreatic cell line.27 Amide, carbamate and urea functional 
groups are also known to promote gelation.2, 3, 4, 21  
Lamivudine 2 has both primary amine and primary alcohol 
functionalities that can be readily derivatized. Modification of the 
alcohol would leave only 1 hydrogen-bond donor in the resultant 
derivatives, which we believed would decrease the potential for 
creation of a self-assembled gelator network based on our 
previous studies.3, 28 We therefore decided to modify the amino 
group to produce amide derivatives 7 of varying chain lengths 
(Table 1, entries 19-21). Prodrugs have been shown to be active 
when administered vaginally; in addition, the increased 
lipophilicity has the potential to increase drug absorption into the 
vaginal epithelium.14  
The gemcitabine and lamivudine derivatives were 
synthesized using known procedures (see Supporting 
Information)19 and were isolated in high purity (≥ 95%) in 
moderate to excellent yields (Table 1). Owing to the relatively high 
cLogP values of compounds in each series (Table 1), gelation 
was approached using an ‘anti-solvent’ system;29 solubilisation of 
the more lipophilic compounds in an organic solvent prior to the 
addition of water was thought to offer the greatest opportunity for 
successful gelation. The derivatives were initially dissolved in 
ethanol at 60°C; water pre-heated to 60°C was then added to 
each solution to achieve a final total volume of 500 μL and a final 
concentration of 0.5 wt% at various solvent volume fractions 
(ΦEtOH). The samples were then allowed to cool to room 
temperature for 18 h before stability to inversion was investigated 
(Figure S1 Supporting Information). The gemcitabine and 
lamivudine derivatives displaying the most promising gel-like 
behaviour in stability to inversion screening (amides 4d and 7b) 
were analysed using TEM (Figure S2 Supporting Information).  
The majority of structures observed in both gels were found to be 
moderately cross-linked, with morphologies ranging from fibres to 
ribbons. Fibre diameters were found to range from 1-40 nm with 
lengths in the range of hundreds of microns. Lamivudine N-amide 
7b exhibited a less densely packed network of fibres to that of 4d.  
Oscillatory rheology tests were used to characterise the 
strength of gel 4d (ΦEtOH 0.05), chosen as representing the best 
from both series. Amplitude sweeps carried out using variable 
strain and constant frequency at 37oC showed storage modulus 
Gʹ was consistently greater than loss modulus Gʺ (Figure 2a), 
suggesting that some cross-linking interactions between 
nanofibres remained intact; G’ was also comparable to that of gels 
used in drug delivery applications, with values typically reported 
in the range of 103 Pa.11, 13, 30 Frequency sweeps were carried out 
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at 37oC under constant strain as determined by the centre of the 
linear viscoelastic region from the amplitude sweep (Figure 2b). 
The sample showed Gʹ values greater then Gʺ, however the 
difference is less than the order of magnitude expected for a 
highly cross-linked nanofibrillar structure.31 The loss factor tan(δ) 
was calculated to be 0.20 – 0.30 and is suggestive of a cross-
linked network with few stabilising linkages between 
morphologies.32 These measurements provide insight as to how 
the gels may behave when administered via injection intra-
tumourally (our targetted application for gemcitabine derivatives). 
This approach has been previoulsy reviewed for polymer gels by 
Wolinsky et al.33 and progressed to porcine preclinical studies for  
Oncogel® - poly(lactide-co-glycolide) and poly(ethylene glycol) 
tri-block copolymer with paclitaxel.34  Whereas we envisage the 
lamivudine derivatives to be applied topicallly. 
Figure 2. Rheological measurements for 4d ΦEtOH 0.05 (0.5 wt%). 
[a] Amplitude sweep carried out γ = 0.1 – 100%, ω = 10 rad s-1, T= 37°C; [b] 
Frequency sweep carried out ω = 0.1 – 100 rad s-1, γ = 1%, T= 37°C, standard 
deviation (G’) 2040 ± 620 Pa. In all cases figures are examples of n = 4. 
 
To investigate in vitro antitumor growth inhibitory properties 
of 4d LMWGs, the (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) colorimetric cell proliferation 
assay was used; activities were compared with that of other 
derivatives displaying gel-like behaviour and the parent 
compound. As gemcitabine is a first-line treatment for pancreatic 
and used to treat gastric cancer, compounds 4d, 5a and 6c along 
with gemcitabine 1 were screened against the human-derived 
MIA PaCa-2 (pancreatic adenocarcinoma) and MKN-7 (gastric 
adenocarcinoma) cell lines to determine test agent concentrations 
that inhibited cell growth by 50% (GI50). To confirm the selectivity 
of the compounds towards these cancer cell lines an additional 
non-transformed cell line was employed (MRC-5 foetal lung 
fibroblast). In the MIA PaCa-2 cell line the GI50 value of 
gemcitabine 1 was found to be 3.02 ± 1.81 nM (Table 2, entry 1). 
Of the other tested compounds 4d was found to have the highest 
activity, yet displayed a 10-fold decrease in growth inhibitory 
activity compared to the parent compound (Table 2, entry 2). 
Compounds 5a and 6c both displayed GI50 values in the 
micromolar range (Table 2, entries 3 and 4), a result consistent 
with recent findings.35 A similar trend was observed in the MKN-7 
cells; gemcitabine 1 demonstrated a GI50 of 13.52 ± 9.66 nM 
(Table 2, entry 1), with compound 4d again displaying the highest 
activity of the gemcitabine derivatives synthesized exhibiting a 
GI50 of 70.85 ± 34.26 nM (Table 2, entry 2). In the literature other 
4-N-alkanoyl gemcitabine derivatives show similar cell growth 
inhibition to the parent compound.  In contrast, the lower potency 
observed for 4d could be attributed to its shorter carbon chain 
length, and hence reduced lipophlicity required to drive passive 
diffusion i.e C8 as compared to 4-N-alkanoyl gemcitabine 
derivatives with C9 to C13 chains lengths as evaluated by Pulido 
et al.25     
Table 2. Solution phase growth inhibition studies for gemcitabine 1 and 
conjugates 3d, 4a and 5c in MIA PaCa-2, MKN-7 and MRC-5 cells.  
 [a] GI50 represents the concentration at which the test agent inhibits cell growth 
by 50%. Assays were carried out in n = 3. 
 
Screening with the MRC-5 fibroblasts demonstrated the 
excellent selectivity of gemcitabine and its analogues towards the 
carcinoma cell lines; a 1000-fold decrease in potency was 
demonstrated for gemcitabine 1, carbamate 5a and urea 6c 
(Table 2, entries 1, 3 and 4) against MRC5 fibroblasts and a 200-
fold decrease was observed for 4d (Table 2, entry 2). Whilst the 
selectivity cannot be qualified without further testing, these results 
support the hypothesis that these gelating entities could be 
potential therapies for localized cancer drug delivery. 
In conclusion, a range of gemcitabine and lamivudine 
derivatives have been synthesized and their ability to form gels 
investigated. Gemcitabine ester series 3 proved to all be generally 
poor gelator agents, likely due to steric hindrance introduced by 
the position of the acyl chain precluding the molecules from 
forming self-assembled networks. Initial screening of the 
gemcitabine amide 4, carbamate 5 and urea 6 series along with 
the lamivudine amide 7 series highlighted a range of promising 
gel combinations involving compounds 4d, 5a, 6c and 7b. TEM 
Entry 
GI50 (nM)[a] 
MIA PaCa-2 MKN-7 MRC-5 
1 1 3.02 ± 1.81 13.52 ± 9.66 > 10000 
2 4d 34.91 ± 13.79 70.85 ± 34.26 2000 ± 560 
3 5a 1430 ± 760 786 ± 100 > 10000 
4 6c 840 ± 460 670 ± 450 > 10000 
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studies showed gels 4d and 7b to be moderately cross-linked 
fibrous networks of varying morphologies. Solution phase growth 
inhibition studies of the gemcitabine derivatives 4d, 5a and 6c 
highlighted amide derivative 4d as displaying the most potent 
activity towards MIA PaCa-2 and MKN-7 carcinoma cell lines with 
nanomolar potency. Further rheology studies for the gemcitabine 
derivative 4d gels confirmed the viscoelastic nature. These 
results demonstrate that gemcitabine amide derivative 4d is 
suitable for further investigation as a chemotherapeutic agent and 
nucleoside based LMWG derivatives are suitable for further 
progression  in localized drug delivery applications including 
vaginal drug delivery.   
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